Cargando…
Immune function in newborns with in-utero exposure to anti-TNFα therapy
BACKGROUND AND AIM: Anti-TNFα is measurable in infants exposed in utero up to 12 months of age. Data about the exposure effect on the infant’s adaptive immunity are limited. We aimed to prospectively evaluate the distribution and function of T and B cells, in infants of females with inflammatory bow...
Autores principales: | Weiss, Batia, Ben-Horin, Shomron, Lev, Atar, Broide, Efrat, Yavzori, Miri, Lahat, Adi, Kopylov, Uri, Picard, Orit, Eliakim, Rami, Ron, Yulia, Avni-Biron, Irit, Yerushalmy-Feler, Anat, Assa, Amit, Somech, Raz, Bar-Gil Shitrit, Ariella |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470929/ https://www.ncbi.nlm.nih.gov/pubmed/36120653 http://dx.doi.org/10.3389/fped.2022.935034 |
Ejemplares similares
-
Ashkenazi Jewish Origin Protects Against Formation of Antibodies to Infliximab and Therapy Failure
por: Ungar, Bella, et al.
Publicado: (2015) -
Do Vedolizumab trough Levels Predict the Outcome of Subsequent Therapy in Inflammatory Bowel Disease?
por: Levartovsky, Asaf, et al.
Publicado: (2023) -
Helicobacter pylori prevalence and clinical significance in patients with quiescent Crohn’s disease
por: Lahat, Adi, et al.
Publicado: (2017) -
Delaying an infliximab infusion by more than 3 days is associated
with a significant reduction in trough levels but not with clinical
worsening
por: Ben-Shatach, Zohar, et al.
Publicado: (2022) -
Serum MMP-9: a novel biomarker for prediction of clinical relapse in patients with quiescent Crohn’s disease, a post hoc analysis
por: Yablecovitch, Doron, et al.
Publicado: (2019)